ArticleJournal of diabetes investigation2025
Inhibition of LINC00707/miR-223-3p/FKBP5 axis has a protective effect on diabetic kidney disease.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LncRNA RAD51-AS1 Alleviates Oxidative Stress and Inflammation in Diabetic Nephropathy by Adsorbing miR-154-5p.Kidney & blood pressure research · 2026Article
- Commentary on: Inhibition of LINC00707/miR-223-3p/FKBP5 axis has a protective effect on diabetic kidney disease.Journal of diabetes investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveResearch indicates that LINC00707 is abnormally expressed in patients suffering from diabetic kidney disease (DKD). Nevertheless, the precise role of LINC00707 in the context of DKD remains enigmatic and warrants further investigation.
methodsInitially, RT-qPCR was employed to assess the expression levels of LINC00707 in patients with DKD. Subsequently, we cultured glomerular podocytes under high-glucose conditions. The effects of LINC00707 on cell proliferation, apoptosis, podocyte functionality (Podocin, Nephrin, and CD2AP), oxidative stress (MDA and SOD), and inflammatory responses (IL-1β, IL-6, and TNF-α) were evaluated using CCK-8, flow cytometry, RT-qPCR, and ELISA assays. Finally, we co-regulated LINC00707 alongside its downstream targets to elucidate the molecular mechanisms by which LINC00707 influences podocyte injury.
resultsLINC00707 is abnormally upregulated in DKD patients. Furthermore, a notable inverse correlation has been observed between LINC00707 levels and renal function in these patients. Upon downregulating LINC00707, we observed an increase in cellular proliferative activity, alongside elevated levels of Podocin, Nephrin, and CD2AP. Concurrently, the reduction of LINC00707 was associated with decreased levels of MDA, as well as proinflammatory cytokines. Significantly, the inhibition of miR-223-3p was found to reverse these observed effects. Further investigation revealed that miR-223-3p directly targets FK506-binding protein 5 (FKBP5).
conclusionsInhibition of LINC00707 may reduce podocyte damage during hyperglycemia by targeting miR-223-3p/FKBP5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.